#aadth ,,congress #b;d ,session ,h4 ,r4 #dfda ,,an ,,act ,to provide for the establishment of an inter-agency task force to review1 modify1 and update best practices for pain management and prescribing pain medication1 and for other purposes4 #a4 ,development of best practices for the use of prescription opioids 7a7 ,definitions ,in this section-- 7#a7 the term ,secretary means the ,secretary of ,health and ,human ,services2 and 7#b7 the term task force means the ,pain ,management ,best ,practices ,inter-,agency ,task ,force convened under subsection 7b74 7b7 ,inter-,agency ,task ,force ,not later than ,december #ad1 #bjah1 the ,secretary1 in cooperation with the ,secretary of ,veterans ,affairs1 the ,secretary of ,defense1 and the ,administrator of the ,drug ,enforcement ,administration1 shall convene a ,pain ,management ,best ,practices ,inter-,agency ,task ,force to review1 modify1 and update1 as appropriate1 best practices for pain management 7including chronic and acute pain7 and prescribing pain medication4 7c7 ,membership ,the task force shall be comprised of-- 7#a7 representatives of-- 7,a7 the ,department of ,health and ,human ,services2 7,b7 the ,department of ,veterans ,affairs2 7,c7 the ,food and ,drug ,administration2 7,d7 the ,department of ,defense2 7,e7 the ,drug ,enforcement ,administration2 7,f7 the ,centers for ,disease ,control and ,prevention2 7,g7 the ,health ,resources and ,services ,administration2 7,h7 the ,indian ,health ,service2 7,i7 the ,national ,academy of ,medicine2 7,j7 the ,national ,institutes of ,health2 7,k7 the ,office of ,national ,drug ,control ,policy2 7,l7 the ,substance ,abuse and ,mental ,health ,services ,administration2 and 7,m7 the ,office of ,women's ,health2 7#b7 ,state medical boards2 7#c7 subject to subsection 7e71 physicians1 dentists1 and nonphysician prescribers2 7#d7 hospitals2 7#e7 subject to subsection 7e71 pharmacists and pharmacies2 7#f7 first responders2 7#g7 experts in the fields of pain research and addiction research2 7#h7 experts in the fields of adolescent and young adult addiction research2 7#i7 representatives of-- 7,a7 pain management professional organizations2 7,b7 the mental health treatment community2 7,c7 the addiction treatment and recovery community2 7,d7 pain advocacy groups2 7,e7 veteran service organizations2 and 7,f7 groups with expertise on overdose reversal2 7#aj7 a person in recovery from addiction to medication for chronic pain2 7#aa7 a person in recovery from addiction to medication for chronic pain1 whose addiction began in adolescence or young adulthood2 7#ab7 a person with chronic pain2 7#ac7 an expert on active duty military1 armed forces personnel1 and veteran health and prescription opioid addiction2 7#ad7 an expert in the field of minority health2 and 7#ae7 other stakeholders1 as the ,secretary determines appropriate4 7d7 ,condition on participation on task force ,an individual representing a profession or entity described in paragraph 7#c7 or 7#e7 of subsection 7c7 may not serve as a member of the task force unless such individual-- 7#a7 is currently licensed in a ,state in which such individual is practicing 7as defined by such ,state7 such profession 7or1 in the case of an individual representing an entity1 a ,state in which the entity is engaged in business72 and 7#b7 is currently practicing 7as defined by such ,state7 such profession 7or1 in the case of an individual representing an entity1 the entity is in operation74 7e7 ,duties ,the task force shall-- 7#a7 not later than #ahj days after the date on which the task force is convened under subsection 7b71 review1 modify1 and update1 as appropriate1 best practices for pain management 7including chronic and acute pain7 and prescribing pain medication1 taking into consideration-- 7,a7 existing pain management research2 7,b7 research on trends in areas and communities in which the prescription opioid abuse rate and fatality rate exceed the national average prescription opioid abuse rate and fatality rate2 7,c7 recommendations from relevant conferences and existing relevant evidence-based guidelines2 7,d7 ongoing efforts at the ,state and local levels and by medical professional organizations to develop improved pain management strategies1 including consideration of differences within and between classes of opioids1 the availability of opioids with abuse deterrent technology1 and pharmacological1 nonpharmacological1 medical device alternatives to opioids to reduce opioid monotherapy in appropriate cases and the coordination of information collected from ,state prescription drug monitoring programs for the purpose of preventing the diversion of pain medication2 7,e7 ongoing efforts at the ,federal1 ,state1 and local levels to examine the potential benefits of electronic prescribing of opioids1 including any public comments collected in the course of those efforts2 7,f7 the management of high-risk populations1 other than populations who suffer pain1 who-- 7i7 may use or be prescribed benzodiazepines1 alcohol1 and diverted opioids2 or 7ii7 receive opioids in the course of medical care2 7,g7 the distinct needs of adolescents and young adults with respect to pain management1 pain medication1 substance use disorder1 and medication-assisted treatment2 7,h7 the #bjaf ,guideline for ,prescribing ,opioids for ,chronic ,pain issued by the ,centers for ,disease ,control and ,prevention2 7,i7 the practice of co-prescribing naloxone for both pain patients receiving chronic opioid therapy and patients being treated for opioid use disorders2 7,j7 research that has been1 or is being1 conducted or supported by the ,federal ,government on prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults relative to any unique circumstances 7including social and biological circumstances7 of adolescents and young adults that may make adolescent-specific and young adult-specific treatment protocols necessary1 including any effects that substance use and substance use disorders may have on brain development and the implications for treatment and recovery2 7,k7 ,federal non-research programs and activities that address prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults1 including an assessment of the effectiveness of such programs and activities in-- 7i7 preventing substance use by and substance use disorders among adolescents and young adults2 7ii7 treating such adolescents and young adults in a way that accounts for any unique circumstances faced by adolescents and young adults2 and 7iii7 supporting long-term recovery among adolescents and young adults2 and 7,l7 gaps that have been identified by ,federal officials and experts in ,federal efforts relating to prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults1 including gaps in research1 data collection1 and measures to evaluate the effectiveness of ,federal efforts1 and the reasons for such gaps2 7#b7 solicit and take into consideration public comment on the practices developed under paragraph 7#a71 amending such best practices if appropriate2 7#c7 develop a strategy for disseminating information about the best practices developed under paragraphs 7#a7 and 7#b7 to prescribers1 pharmacists1 ,state medical boards1 educational institutions that educate prescribers and pharmacists1 and other parties1 as the ,secretary determines appropriate2 7#d7 review1 modify1 and update best practices for pain management and prescribing pain medication1 specifically as it pertains to physician education and consumer education2 and 7#e7 examine and identify-- 7,a7 the extent of the need for the development of new pharmacological1 nonpharmacological1 and medical device alternatives to opioids2 7,b7 the current status of research efforts to develop such alternatives2 and 7,c7 the pharmacological1 nonpharmacological1 and medical device alternatives to opioids that are currently available that could be better utilized4 7f7 ,consideration of study results ,in reviewing1 modifying1 and updating1 best practices for pain management and prescribing pain medication1 the task force shall take into consideration existing private sector1 ,state1 and local government efforts related to pain management and prescribing pain medication4 7g7 ,limitation ,the task force shall not have rulemaking authority4 7h7 ,report ,not later than #bgj days after the date on which the task force is convened under subsection 7b71 the task force shall submit to ,congress a report that includes-- 7#a7 the strategy for disseminating best practices for pain management 7including chronic and acute pain7 and prescribing pain medication1 as developed under subsection 7e72 7#b7 the results of a feasibility study on linking the best practices described in paragraph 7#a7 to receiving and renewing registrations under section #cjc7;f7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7;f772 7#c7 recommendations for effectively applying the best practices described in paragraph 7#a7 to improve prescribing practices at medical facilities1 including medical facilities of the ,veterans ,health ,administration and ,indian ,health ,service2 7#d7 the modified and updated best practices described in subsection 7e77#d72 and 7#e7 the results of the examination and identification conducted pursuant to subsection 7e77#d71 and recommendations regarding-- 7,a7 the development of new pharmacological1 nonpharmacological1 and medical device alternatives to opioids2 and 7,b7 the improved utilization of pharmacological1 nonpharmacological1 and medical device alternatives to opioids that are currently available4 ,passed the ,house of ,representatives ,may #aa1 #bjaf4;,clerk4